Sanofi Acquires Vigil Neuroscience for $470M to Advance Alzheimer’s TREM2 Drug

Reviving TREM2's Therapeutic Promise After Past Setbacks

In a move aimed at revitalizing interest in TREM2-targeted Alzheimer’s therapies, Sanofi has announced the acquisition of Vigil Neuroscience for approximately $470 million upfront. The acquisition follows a turbulent period for the TREM2 drug target, which had seen waning investor enthusiasm after the failure of a similar therapy developed by AbbVie and Alector in 2024. As part of the agreement, Vigil shareholders will receive $8 per share—a 250% premium over its prior trading price—plus a potential $2 per share through a contingent value right (CVR), bringing the total deal value up to $600 million.

Strategic Fit and Synergy

Sanofi’s head of R&D, Houman Ashrafian, emphasized that the acquisition supports the French pharmaceutical company’s broader strategic focus on neurology. He noted, “TREM2 represents a compelling target at the intersection of immune dysregulation and neurodegeneration, particularly in people living with Alzheimer’s because they face devastating cognitive decline with limited treatment options.”

Vigil CEO Ivana Magov?evi?-Liebisch expressed optimism about the acquisition, stating the deal will allow Vigil to benefit from “Sanofi’s resources, broad platform and far-reaching network” to advance development of its lead TREM2 small molecule VG-3927.

Deal Dynamics and Market Implications

Analysts at Stifel noted the high premium paid by Sanofi likely reflects a competitive acquisition process, even though the $8 per share is below Vigil’s 2022 IPO price of $14. “Even though $8 is below IPO price, it represents a nearly 250% premium (seemingly [a] competitive process?), while the broader market has changed, and the TREM2 story has become more nuanced,” Stifel stated in a research note.

The deal, expected to close in Q3 2025, excludes Vigil’s lead monoclonal antibody program iluzanebart (VGL101), which is being returned to Amgen, its original licensor. That program was focused on adult-onset leukoencephalopathy and had sought accelerated FDA approval without recent updates.

TREM2’s Checkered History

The TREM2 target has faced considerable skepticism following the November 2024 failure of AbbVie and Alector’s AL002 in a Phase II Alzheimer’s trial. The study showed no significant improvements in symptoms, biomarkers, or functional outcomes, and highlighted safety concerns such as amyloid-related imaging abnormalities (ARIA).

Stifel analysts, however, drew a clear distinction between AL002 and Vigil’s VG-3927, citing superior biochemical characteristics and a different mechanism of action. While public investor sentiment remained cautious, early data on VG-3927 indicated promising brain penetration, safety, and a 50% reduction in sTREM2—a biomarker linked with early Alzheimer’s symptoms.

Future Outlook for VG-3927

VG-3927 completed its Phase I trial earlier this year, and a Phase II study is anticipated to begin in Q3 2025. Sanofi’s acquisition follows a $40 million development capital investment in July 2024, during which Sanofi secured first refusal rights for VG-3927. This latest move marks a strategic expansion in the company’s Alzheimer’s portfolio, aligning it with recent industry advancements such as the FDA approval of Biogen and Eisai’s Leqembi in 2023 and Eli Lilly’s Kisunla in 2024.

Stifel concluded, “For these reasons—and considering the strong scientific rationale behind TREM2—it’s not shocking that another company is enthusiastic to re-test the thesis in AD.”

Highlights

• Sanofi acquires Vigil Neuroscience for $470M upfront, with the total deal potentially reaching $600M including CVRs.
• The acquisition revives interest in TREM2-based therapies following AbbVie and Alector’s clinical failure.
• Vigil’s VG-3927 has shown promising Phase I results, with a Phase II trial planned for Q3 2025.
• Sanofi is not acquiring Vigil’s lead antibody program VGL101, which will return to Amgen.
• This deal aligns with Sanofi’s strategic focus on neurology and Alzheimer’s disease innovation.